Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

BRD4-N CRISPR (#RDB18359)

Expression vector of Cas9 and gRNA for a BRD4 tagging donor.

Clone info. Expression vector of Cas9 and gRNA for a BRD4 tagging donor, see Fig. 5 of Yesbolatova, A. et al., Nat. Commun. 11: 5701, 2020.
Vector backbone px330 (plasmid)
Selectable markers Ampicillin
Gene/insert name human BRD4 cDNA
Depositor|Developer Kanemaki, Masato |
 
Sequence (full) RDB18359zzk01.seq provided by the depositor

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
Exclusive MTA (For the DNA materials containing CRISPR/Cas9 technologies and for not-for-profit academic purpose) [Word]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested (Yesbolatova, A. et al., Nat. Commun. 11: 5701 (2020)).
Remarks
The BIOLOGICAL RESOURCE contains CRISPR/Cas9 technologies and is not provided to for-profit organization or for for-profit research by non-profit organizations.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
専用MTA（CRISPR/Cas9内包遺伝子材料専用 非営利学術目的）をお使いください [Word]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Yesbolatova, A. et al., Nat. Commun. 11: 5701 (2020))。
備考
本件リソースはCRISPR/Cas9 technologyを用いたゲノム編集バイオリソースです。営利機関および非営利機関による営利目的研究には提供いたしません。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB18359 BRD4-N CRISPR DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The BRD4-N CRISPR was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB18359).

Reference section:

Yesbolatova, A., Saito, Y., Kitamoto, N., Makino-Itou, H., Ajima, R., Nakano, R., Nakaoka, H., Fukui, K., Gamo, K., Tominari, Y., Takeuchi, H., Saga, Y., Hayashi, K., Kanemaki, M.T., The auxin-inducible degron 2 technology provides sharp degradation control in yeast, mammalian cells, and mice. Nat. Commun. 11: 5701 (2020). PMID 33177522. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB18359_B0Gfp1-1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: SV40pA3element Reverse (Pr0108)
Region: U6 pro,sgRNA for BRD4-N,CBh pro
Sequence file: RDB18359_B0Gfa.seq check
>D07105C9_B0Gf_3_SV40pA3'element Reverse_A05_02_ABI24.ab1
    1 NNNNNNNNNN NNNNNGNNNN NANGGNNNNN NCNNGCAACG CGGCCTTTTT ACGGTTCCTG
   61 GCCTTTTNNN NNNNNNTTGC TCACATGTGA GGGCCTATTT CCCATGATTC CNTCNTATTT
  121 GCATATACGA TACAAGGCTG TTAGAGAGAT AATTGGAATT AATTTGACTG TAAACACAAA
  181 GATATTAGTA CAAAATACGT GACGTAGAAA GTAATAATTT CTTGGGTAGT TTGCAGTTTT
  241 AAAATTATGT TTTAAAATGG ACTATCATAT GCTTACCGTA ACTTGAAAGT ATTTCGATTT
  301 CTTGGCTTTA TATATCTTGT GGAAAGGACG AAACACCGAT GTCTGCGGAG AGCGGCCCGT
  361 TTTAGAGCTA GAAATAGCAA GTTAAAATAA GGCTAGTCCG TTATCAACTT GAAAAAGTGG
  421 CACCGAGTCG GTGCTTTTTT GTTTTAGAGC TAGAAATAGC AAGTTAAAAT AAGGCTAGTC
  481 CGTTTTTAGC GCGTGCGCCA ATTCTGCAGA CAAATGGCTC TAGAGGTACC CGTTACATAA
  541 CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC CCCGCCCATT GACGTCAATA
  601 GTAACGCCAA TAGGGACTTT CCATTGACGT CAATGGGTGG AGTATTTACG GTAAACTGCC
  661 CACTTGGCAG TACATCAAGT GTATCATATG CCAAGTACGC CCCCTATTGA CGTCAATGAC
  721 GGTAAATGGC CCGCCTGGCA TTGTGCCCAG TACATGACCT TATGGGACTT TCCTACTTGG
  781 CAGTACATCT ACGTATTANT CATCGCTATT ACCATGGTCG ANGTGANCCC CACGTTCTGC
  841 TTCACTCTCC CCATCTCCCC CCCCNNNCCN ACCCCCAATT TTGTANTTAT TTATTTTTTN
901 NATTATTTTG TGCANCGATG GGGGCGNNNN NNNNNN
//
Primer: bGH_rev3 (Pr0885)
Region: nucleoplasmin NLS,Cas9
Sequence file: RDB18359_B0Gfb.seq check
>D07105C9_B0Gf_3_bGH_rev3_G01_07_ABI08.ab1
    1 NNNNNNNNNN NNNNNNNNNN NNNGGGNNGG NNNNNNACNG ANGGCTGGCA ACTAGAAGGC
   61 ACAGTCGAGG CTGATCAGCN AGCTCTAGGA ATTCTTACTT TTTCTTTTTT GCCTGGCCGG
  121 CCTTTTTCGT GGCCGCCGGC CTTTTGTCGC CTCCCAGCTG AGACAGGTCG ATCCGTGTCT
  181 CGTACAGGCC GGTGATGCTC TGGTGGATCA GGGTGGCGTC CAGCACCTCT TTGGTGCTGG
  241 TGTACCTCTT CCGGTCGATG GTGGTGTCAA AGTACTTGAA GGCGGCAGGG GCTCCCAGAT
  301 TGGTCAGGGT AAACAGGTGG ATGATATTCT CGGCCTGCTC TCTGATGGGC TTATCCCGGT
  361 GCTTGTTGTA GGCGGACAGC ACTTTGTCCA GATTAGCGTC GGCCAGGATC ACTCTCTTGG
  421 AGAACTCGCT GATCTGCTCG ATGATCTCGT CCAGGTAGTG CTTGTGCTGT TCCACAAACA
  481 GCTGTTTCTG CTCATTATCC TCGGGGGAGC CCTTCAGCTT CTCATAGTGG CTGGCCAGGT
  541 ACAGGAAGTT CACATATTTG GAGGGCAGGG CCAGTTCGTT TCCCTTCTGC AGTTCGCCGG
  601 CAGAGGCCAG CATTCTCTTC CGGCCGTTTT CCAGCTCGAA CAGGGAGTAC TTAGGCAGCT
  661 TGATGATCAG GTCCTTTTTC ACTTCTTTGT AGCCCTTGGC TTCCAGAAAG TCGATGGGAT
  721 TCTTCTCGAA NCTGCTTCTT TCCATGATGG TGATCCCCAG CAGCTCTTTC ACACTCTTCA
  781 NTTTCTTGGA CTTGCCCTTT TCCACTTTGG NCNCCACNNN NNNNNAATAN GCCACGGTGG
  841 GGCTGTCNNN NNNNCNNNAC TTCTTAGGGT CCCAGTCCTT CTTTCTGGCG ATNANCTTAN
  901 CNCTGNTCCT CNTGNNNNNG ANANANTCTT TNCTNNANNC CNCNTGNCNG NNNNTCNGNN
  961 CNTTTTCNCN ATATTCACNN NGGGNNNNGC TNNANNNNNT TCCNCNNGGN GGNCNAANNC
 1021 CCGGNCCNTN ATCCCNCNNN NATNNNCCNN NTTNCNNNGT NNGNCNNGAT NNNANNNNNN
1081 NNCNNNNNNN NNN
//
Primer: Cas9-N_R1 (Pr0650)
Region: CBh pro,3xFLAG, SV40 NLS,Cas9
Sequence file: RDB18359_B0Gfc.seq check
>D07105C9_B0Gf_3_Cas9-N_R3_H01_08_ABI08.ab1
    1 NNNNNNNNNN NNNNNNNNNN NNNNNGNCGA NGTCNNGGCC GANGCTGTAC TTCTTGTCGG
   61 CTGCTGGGAC TCCGTGGATA CCGACCTTCC GCTTCTTCTT TGGGGCCATC TTATCGTCAT
  121 CGTCTTTGTA ATCAATATCA TGATCCTTGT AGTCTCCGTC GTGGTCCTTA TAGTCCATGG
  181 TGGCACCGGT CCAACCTGAA AAAAAGTGAT TTCAGGCAGG TGCTCCAGGT AATTAAACAT
  241 TAATACCCCA CCAACCAACC ATCCCTTAAA CCCTTACCTC TTGCTCAGCT AATTACAGCC
  301 CGGAGGAGAA GGGCCGTCCC GCCCGCTCAC CTGTGGGAGT AACGCGGTCA GTCAGAGCCG
361 GGGCGGGCGG CGCGAGG
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Yesbolatova, A., The auxin-inducible degron 2 technology provides sharp degradation control in yeast, mammalian cells, and mice. Nat. Commun. 11: 5701 (2020). PMID 33177522. [link to RRC of NBRP]